Navigation Links
CHPA Statement on PSE Economic Study By AEI Fellow Alex Brill
Date:3/8/2013

WASHINGTON, March 8, 2013 /PRNewswire-USNewswire/ -- The Consumer Healthcare Products Association (CHPA) released a statement today on a recent study conducted by American Enterprise Institute fellow Alex Brill and supported by a grant from CHPA. Brill previously served as the chief economist for the U.S. House Committee on Ways and Means from 2002-2007.  His economic policy consulting firm, Matrix Global Advisors, published the study March 4.

With consideration to both the economic costs on the healthcare system and consumers, the study examines the unintended impacts of a prescription-only policy for cold and allergy medicines containing pseudoephedrine (PSE) and finds:

  • Extra doctor visits, contributing $59 million in additional costs to the government, consumers, and private insurance companies in the first year following the policy's implementation;
  • More absenteeism and lost work productivity, when the common cold already costs this nation an estimated $25 billion annually in lost productivity;
  • Higher prices for PSE medicines due to the overall cost difference between a prescription-only product and an over-the-counter one;
  • Increased health insurance premiums due to additional doctor visits and higher PSE drug costs;
  • An estimated loss of $219.2 million in state tax revenues over ten years.

"There is no question that certain states struggle with domestic methamphetamine production," said Alex Brill , chief executive officer of Matrix Global Advisors. "However, my analysis left me convinced that the serious economic and social consequences of a prescription requirement, coupled with the dominance of Mexican drug cartels in the American meth market, should give lawmakers pause before pursuing such a policy."

"Recent consumer surveys clearly demonstrate that law-abiding citizens oppose legislation that would force them to consult with a doctor in order to buy the cold and allergy medicines of their choice," said David Spangler , senior vice president, policy and general counsel at CHPA. "This study provides us with a better understanding of the consumer burden by quantifying the economic impact a prescription requirement would have—most importantly  on consumers— but also on businesses and state governments as well."

Editor's note: To access Brill's complete study, visit http://www.matrixglobaladvisors.com/storage/PSE.pdf

CHPA is the 132-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and dietary supplements.

chpa-info.org


'/>"/>
SOURCE Consumer Healthcare Products Association
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
2. CHPA Statement on Statewide Indiana Consumer Poll
3. Sonitus Medical Announces Affirmative Update Regarding Bone Conduction Oral Appliances in American Academy of Otolaryngology-Head and Neck Surgery Policy Statement on Implantable Hearing Devices
4. Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients
5. Statement from Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on the Front Page New York Times Story Regarding the Pre-emptive Strikes of Amgen/Genentech to Restrict Access to Affordable and Safe Biosimilars
6. Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory
7. Hill-Rom Reports Fiscal First Quarter Results; Updates 2013 Financial Outlook For R&D Tax Credit Reinstatement
8. CVS Caremark Statement and Response to CMS Action
9. World Renowned Scientist, Dr. Rongxiang Xu Speaks Out About Nobel Assembly Statement Claiming They Have Not Heard Of Him
10. STATEMENT OF CHAIRMAN AND CEO GEORGE BARRETT FORTUNE 21 CARDINAL HEALTH REGARDING FISCAL CLIFF
11. PCMA Statement on Essential Health Benefits Proposed Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... , media relations, content marketing, social media management, corporate communications, SEO and cause ... the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus ...
(Date:2/23/2017)... Colorado (PRWEB) , ... February 23, 2017 , ... ... Magazine, an exciting, new, interactive publication where generations converge and explore the world ... expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... new partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) ... for children with autism spectrum disorder (ASD) to see films in an environment ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... York (PRWEB) , ... February 22, 2017 , ... ... entrance and lobby of a new healthcare contact center in Georgia, PENETRON Specialty ... One of the nation’s largest healthcare systems recently invested $51 million to purchase ...
Breaking Medicine News(10 mins):